| Paroxysmal Nocturnal Hemoglobinuria |
1 |
1 |
| Primary Immunodeficiency |
0 |
0.5 |
| Blood |
0 |
0.43 |
| Otolaryngology |
0 |
0.42 |
| COVID-19 |
0 |
0.33 |
| Urinary Tract Infection |
0 |
0.25 |
| Anemia |
0 |
0.22 |
| Bacteria |
0 |
0.22 |
| Hemoglobin |
0 |
0.22 |
| Nasopharyngitis |
0 |
0.22 |
| Transfusion |
0 |
0.22 |
| Pain Management |
0 |
0.21 |
| Patient Safety |
0 |
0.21 |
| Pneumonia |
0 |
0.21 |
| Revenue and Practice Management |
0 |
0.21 |
| Abdominal Pain |
0 |
0.19 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.18 |
| Diarrhea |
0 |
0.12 |
| Headache |
0 |
0.12 |
| Abdomen |
0 |
0.11 |
| Bacterial Pneumonia |
0 |
0.11 |
| California |
0 |
0.11 |
| Cancer |
0 |
0.11 |
| Food and Drug Administration (FDA) |
0 |
0.11 |
| Immunization |
0 |
0.11 |
| Nausea |
0 |
0.11 |
| Pain |
0 |
0.11 |
| Pyelonephritis |
0 |
0.11 |
| Viral Infection |
0 |
0.11 |